147 related articles for article (PubMed ID: 17881539)
1. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C.
Persico M; Capasso M; Russo R; Persico E; Crocè L; Tiribelli C; Iolascon A
Gut; 2008 Apr; 57(4):507-15. PubMed ID: 17881539
[TBL] [Abstract][Full Text] [Related]
2. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
[TBL] [Abstract][Full Text] [Related]
3. Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.
Pascarella S; Clément S; Dill MT; Conzelmann S; Lagging M; Missale G; Neumann AU; Pawlotsky JM; Zeuzem S; Rubbia-Brandt L; Bochud PY; Negro F
Liver Int; 2013 Jan; 33(1):94-103. PubMed ID: 23164156
[TBL] [Abstract][Full Text] [Related]
4. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection.
Kim KA; Lin W; Tai AW; Shao RX; Weinberg E; De Sa Borges CB; Bhan AK; Zheng H; Kamegaya Y; Chung RT
J Hepatol; 2009 Apr; 50(4):705-11. PubMed ID: 19231005
[TBL] [Abstract][Full Text] [Related]
5. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
Asselah T; Bieche I; Narguet S; Sabbagh A; Laurendeau I; Ripault MP; Boyer N; Martinot-Peignoux M; Valla D; Vidaud M; Marcellin P
Gut; 2008 Apr; 57(4):516-24. PubMed ID: 17895355
[TBL] [Abstract][Full Text] [Related]
6. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients.
Zekri AR; Abdullah D; Osman A; El-Rouby MN; Zayed N; Esmat G; Elakel W; Hafez HA
Arab J Gastroenterol; 2015; 16(3-4):84-9. PubMed ID: 26526510
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of the cytokine milieu associated with the up-regulation of IL-6 and suppressor of cytokine 3 in chronic hepatitis C treatment non-responders.
Martinez D; Palmer C; Simar D; Cameron BA; Nguyen N; Aggarwal V; Lloyd AR; Zekry A
Liver Int; 2015 Feb; 35(2):463-72. PubMed ID: 24461080
[TBL] [Abstract][Full Text] [Related]
9. Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.
Honda M; Takehana K; Sakai A; Tagata Y; Shirasaki T; Nishitani S; Muramatsu T; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shimakami T; Yi M; Lemon SM; Suzuki T; Wakita T; Kaneko S;
Gastroenterology; 2011 Jul; 141(1):128-40, 140.e1-2. PubMed ID: 21458454
[TBL] [Abstract][Full Text] [Related]
10. Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
Ali FT; Ali MA; Elgizawy MM; Elsawy AM
Gut Liver; 2015 Jul; 9(4):516-24. PubMed ID: 25717047
[TBL] [Abstract][Full Text] [Related]
11. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
13. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
14. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
17. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
19. SOCS3 mRNA expression and polymorphisms as pretreatment predictor of response to HCV genotype 3a IFN-based treatment.
Aslam R; Raza SM; Naeemi H; Mubarak B; Afzal N; Khaliq S
Springerplus; 2016; 5(1):1826. PubMed ID: 27818864
[TBL] [Abstract][Full Text] [Related]
20. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
